Provention Bio Inc. Stock News

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of Radia

Get an early start on the events of the day.

Get an early start on the events of the day.

It could be a make-or-break end of the year for the company.

It could be a make-or-break end of the year for the company.

Upgrades UBS upgraded the previous rating for America Movil SAB de CV (NYSE:AMX) from Neutral to Buy. America Movil earned $0.21 in the second quarter, compared to $0.64 in the year-ago quarter. At th

RED BANK, N.J. , Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that m

It's been a wild 12 months for these companies.

It's been a wild 12 months for these companies.

Provention Bio, Inc. (NASDAQ:PRVB ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Robert Doody - Vice President, Investor Relations Thierry Chauche - Chief Financial

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RED BANK, N.J. , July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that i

Are the Street's predictions too optimistic?

Are the Street's predictions too optimistic?